newsfilter
← Latest News
GlobeNewswire·

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RNXT
  • RenovoRx reported Q1 2026 revenue of $563,000, representing a 136% increase from Q4 2025 & exceeding 50% of total 2025 revenue.
  • Active commercial cancer center customers expanded to 16 as of May 6, 2026, with 32 additional centers in the sales pipeline.
  • The company maintains $12.4 million in cash & cash equivalents, sufficient to fund operations into at least the second half of 2027.
  • Phase III TIGeR-PaC trial enrollment is projected to reach full completion by June 2026, with 106 of 114 required patients randomized as of May 14, 2026.
  • Full-year 2026 revenue guidance is reiterated at $3 million to $4 million.
  • Research & development expenses were $1.2 million in Q1 2026, down from $1.6 million in the prior year, while SG&A expenses rose to $2.7 million.
  • Net loss for the quarter ended March 31, 2026, was approximately $3.5 million, compared to $2.4 million in the same period of 2025.
  • A private placement completed in March 2026 generated approximately $10 million in gross proceeds to support working capital & growth initiatives.
  • RenovoCath has been used in 750 successful procedures since FDA clearance in 2014, & the company was named one of Fast Company's "World's Most Innovative Companies of 2026."
  • Management plans to host a conference call on May 14, 2026, at 4:30 P.M. ET to discuss these financial results & business updates.